Dendrite's Flagship Sales Force Effectiveness Solution Available on Microsoft SQL Server

Dendrite International, Inc. (NASDAQ:DRTE) a leading
provider of pharmaceutical industry solutions, today announced that it
will make its flagship sales force effectiveness solution, Mobile
Intelligence(TM), available on Microsoft SQL Server 2005 in the fourth
quarter. This strategic decision was made to provide its customers
with additional options that may result in a lower total cost of
ownership.
   Dendrite's Mobile Intelligence incorporates a revolutionary,
human-centered design that mirrors the workflow of the representative.
It enables users to be more efficient and effective in their detailing
activity by providing access to all the information they require on a
customer call with a few keystrokes. By developing Mobile intelligence
using Microsoft .NET technologies, one of the world's most widely
accepted development environments, Dendrite has ensured maximum
flexibility for integration into its customers' existing
infrastructure while reducing total cost of ownership.
   "Dendrite's objective is to enable a wide range of pharmaceutical
companies to capitalize on our solutions for competitive advantage,"
said Mark Theilken, Dendrite's president of Sales Solutions. "The
global pharmaceutical industry is evolving rapidly and every company
has unique circumstances that require a flexible, adaptable solution
set. Our latest version of Mobile Intelligence ensures that a wider
universe of pharmaceutical companies, regardless of size or geography,
can benefit from this flexibility."
   "SQL Server 2005 is a well-established and proven technology in
the pharmaceutical market," said Steve Shihadeh, general manager,
healthcare and life sciences, Microsoft. "Dendrite's innovative use of
Microsoft technology provides seamless integration with desktop
applications, enabling users to better connect and collaborate,
ultimately allowing them to make more informed business decisions."

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global
pharmaceutical industry. The company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies. For more information, please visit www.dendrite.com.

   Note: Dendrite and the Dendrite product names mentioned herein are
the trademarks or registered trademarks of Dendrite International,
Inc. The names of other companies or products mentioned herein may be
the trademarks of their respective owners.

   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements.